Bosh sahifaATYR • NASDAQ
add
aTyr Pharma Inc
3,03 $
Seans yopilganidan keyin:(1,98%)+0,060
3,09 $
Yopilgan:22-noy, 17:03:35 (GMT-5) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
2,98 $
Kunlik diapazon
2,95 $ - 3,19 $
Yillik diapazon
1,42 $ - 3,19 $
Bozor kapitalizatsiyasi
254,35 mln USD
Oʻrtacha hajm
1,28 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 3,34 mln | 25,93% |
Sof foyda | -17,26 mln | -52,20% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -0,23 | -15,00% |
EBITDA | -17,96 mln | -44,42% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 65,99 mln | -35,39% |
Jami aktivlari | 91,62 mln | -26,75% |
Jami passivlari | 26,48 mln | -1,45% |
Umumiy kapital | 65,14 mln | — |
Tarqatilgan aksiyalar | 83,94 mln | — |
Narxi/balansdagi bahosi | 3,47 | — |
Aktivlardan daromad | -45,92% | — |
Kapitaldan daromad | -52,14% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -17,26 mln | -52,20% |
Operatsiyalardan naqd pul | -13,16 mln | -37,65% |
Sarmoyadan naqd pul | 17,95 mln | 309,45% |
Moliyadan naqd pul | -105,00 ming | -103,91% |
Naqd pulning sof oʻzgarishi | 4,68 mln | 287,77% |
Boʻsh pul | -6,49 mln | -12,66% |
Haqida
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Tashkil etilgan
1-yan, 2005
Sayt
Xodimlar soni
58
